Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) EV-to-EBITDA : -5.75 (As of May. 05, 2024)

Keryx Biopharmaceuticals EV-to-EBITDA Chart

Keryx Biopharmaceuticals Annual Data
	Trend	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17
EV-to-EBITDA		Get a 7-Day Free Trial					-20.89	-11.63	-4.05	-5.30	-5.61

Keryx Biopharmaceuticals Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
EV-to-EBITDA	Get a 7-Day Free Trial															-6.68	-5.61	-5.24	-6.96	-6.06

Competitive Comparison of Keryx Biopharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, Keryx Biopharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Keryx Biopharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keryx Biopharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Keryx Biopharmaceuticals's EV-to-EBITDA falls into.

Keryx Biopharmaceuticals EV-to-EBITDA Calculation

Keryx Biopharmaceuticals's EV-to-EBITDA for today is calculated as:

Keryx Biopharmaceuticals's current Enterprise Value is $510.62 Mil.
Keryx Biopharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-88.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Keryx Biopharmaceuticals  (NAS:KERX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Keryx Biopharmaceuticals's PE Ratio (TTM) for today is calculated as:

Keryx Biopharmaceuticals's share price for today is $3.36.
Keryx Biopharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.750.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Keryx Biopharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Keryx Biopharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Business Description